A·Agilent Technologies, Inc.
A|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.49 | - | - |
| Q2'26 | $1.44 | $1.49 | +3.8% |
| Q1'26 | $1.40 | $1.36 | -2.6% |
| Q3'25 | $1.58 | $1.59 | +0.4% |
| Q2'25 | $1.37 | $1.37 | +0.2% |
| Q1'25 | $1.26 | $1.31 | +3.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.9B | - | - |
| Q2'26 | $1.8B | $1.8B | +0.0% |
| Q1'26 | $1.8B | $1.8B | -2.4% |
| Q3'25 | - | $1.9B | - |
| Q2'25 | - | $1.7B | - |
| Q1'25 | - | $1.7B | - |
Market Data
A Stock Snapshot
A is currently trading at $158.96, giving Agilent Technologies, Inc. a market cap of 41.52B and a P/E ratio of 29.4. Today's range spans $155.24–$160.51, with shares opening at $156.50 and moving up $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 82/100.
Over the past year A has traded between $108.35 and $160.27 - the current price is +46.7% off the 52-week low and -0.8% from the high.
Short interest data on large-cap Healthcare names like A (41.52B market cap) becomes relevant when the technical picture turns bullish - a BUY on 82/100 with bullish sentiment (82/100) is exactly the kind of setup that makes shorts nervous. Price at $158.96 (near 52-week highs in $108.35–$160.27). The current P/E ratio stands at 29.4. Short covering in a bullish technical phase can add a secondary momentum layer on top of genuine long-side conviction - a dynamic worth monitoring in the current setup.
What makes A's BUY setup (82/100) particularly actionable at 41.52B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $158.96 (near 52-week highs in $108.35–$160.27), with sentiment running bullish at 82/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: Agilent Technologies (A)
Agilent Technologies, Inc. generates most of its revenue in the United States, yet its European operations account for roughly a third of sales, as evidenced by the recent EU approval of its PD‑L1 IHC 22C3 companion diagnostic for ovarian cancer. The company’s global footprint also includes a growing presence in Asia‑Pacific, where laboratory services demand is rising faster than in mature markets. Currency risk is material: about 25% of sales are invoiced in euros, exposing earnings to fluctuations in the EUR/USD pair that can compress margins if the euro strengthens against the dollar. Recent sentiment analysis shows a 14‑day falling trend with a score of 77, suggesting that negative news may be weighing on the stock’s short‑term outlook. The company’s 52‑week range of $108.35 to $160.27 places it 24% above the low, while the analyst consensus target of $159.32 sits just below the high, indicating limited upside if the price stays near the peak.
The firm’s recent FDA and European regulatory approvals have opened new oncology segments, notably the companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. This expansion is expected to drive both test‑kit and consumable sales, with early adoption trends suggesting a 10‑15% lift in diagnostics revenue over the next fiscal year. However, margin compression concerns have been raised by Argus Research, citing rising consumable costs and increased competition from lower‑cost generics. Agilent’s investment in HALO X‑ray Technologies seeks to diversify revenue streams and mitigate potential erosion in traditional assay sales. The company’s forward earnings trajectory remains robust, with Q2 2026 EPS of $1.49 beating estimates and revenue of $1.835 billion surpassing guidance.
From a valuation standpoint, Agilent trades at a forward P/E of 28.7, well below the peer average of 52.1 across AbbVie, Abbott, Align, and Amgen, offering a discount to the sector. Analyst consensus places a mean target of $159.32, implying only a modest upside from the current price of $145.97, while the 52‑week high of $160.27 limits near‑term upside potential. The company’s market cap of $40.6 billion and strong buy‑hold ratings (22 buy, 7 hold) reflect confidence in its earnings momentum. Yet, currency volatility and regulatory uncertainties remain key risks that could undermine earnings if not managed effectively.
The 1‑year price return of just 0.6% indicates limited upside from recent performance, underscoring the importance of timing entry points. A decline in euro value could erode margins, while successful EU approvals and partnership uptake could accelerate revenue growth. Investors should monitor Q3 FY2026 earnings guidance, reimbursement decisions, and any new regulatory approvals that could act as catalysts. In sum, Agilent presents a valuation discount coupled with geographic growth potential, but requires careful attention to FX exposure and margin dynamics.
The company’s multi‑channel distribution model, combining direct sales with strategic partnerships, ensures broad market access and supports its expansion into emerging diagnostic markets. By leveraging its cross‑lab services and applied markets segments, Agilent can cross‑sell solutions and increase customer stickiness. The recent EU certification enhances its competitive position against rivals such as Abbott and Amgen in the oncology diagnostics space. Continued investment in technology platforms like HALO X‑ray may open new revenue avenues and reinforce Agilent’s long‑term growth trajectory. However, the firm must navigate regulatory timelines and reimbursement pathways to fully realize the upside of its expanded product portfolio.
Global Footprint
U.S. sales represent 55% of revenue, while European market accounts for 30%, and Asia-Pacific growth is accelerating through expanding laboratory services.
Approximately 25% of sales are denominated in euros, exposing earnings to EUR/USD swings that can affect margin if currency moves against the company.
Recent EU certification of the PD‑L1 IHC 22C3 assay expands market to ovarian, fallopian tube, and peritoneal cancers, potentially boosting kit sales.
FX Sensitivity
About 25% of Agilent’s revenue is invoiced in euros, creating exposure to EUR/USD fluctuations that can compress margins if the euro strengthens.
The company uses forward contracts to hedge currency risk, yet residual exposure remains due to the timing of sales and settlement cycles.
A sudden devaluation of the euro could increase the cost of imported consumables, impacting net income.
Oncology Catalyst
EU approval of the PD‑L1 IHC 22C3 companion diagnostic opens a new oncology segment for ovarian and peritoneal cancers.
The partnership with Merck to flag patients for Keytruda therapy could drive both kit and consumable sales, creating a new revenue stream.
Early adoption data suggest a 10‑15% lift in diagnostics revenue in the next fiscal year, providing a clear growth catalyst.
Valuation Edge
Agilent trades at a forward P/E of 28.7, well below the peer average of 52.1, offering a discount to the sector.
Analyst consensus target of $159.32 implies only modest upside from the current price of $145.97, while the 52‑week high of $160.27 limits near‑term upside potential.
The company’s market cap of $40.6 billion and strong buy‑hold ratings reflect confidence in its earnings momentum.
Margin Pressure
Argus Research flagged margin compression from rising consumable costs, raising concerns about profitability.
Competition from lower‑cost generics could erode pricing power in the diagnostics market, threatening margin stability.
Investments in HALO X‑ray Technologies aim to diversify revenue streams and offset potential erosion in traditional assay sales.
Positioning A
Consider adding Agilent when the share price approaches its 52‑week low, offering a 24% buffer from the low and a falling sentiment trend over the past 14 days. The analyst consensus target of $159.32 sits just below the 52‑week high of $160.27, implying limited upside if the stock trades near that level. A moderate upside exists if the price reverts to the 52‑week midpoint around $134.31, providing a 20% upside over the current price of $145.97. Increase exposure if the company secures additional EU approvals or sees uptake of its companion diagnostic partnership, potentially lifting diagnostics revenue by 10‑15%. Reduce exposure if euro depreciation accelerates, eroding margin, or if the company fails to meet its Q3 FY2026 earnings guidance. Overall, a balanced allocation that reflects the company’s valuation discount and geographic growth potential is advisable.
Key Metrics for A
Agilent’s valuation hinges on how its diagnostics platform expands across regions, how consumable margins hold up amid cost pressures, and how regulatory approvals unlock new revenue streams. These dynamics shape the company’s earnings rhythm and influence investor sentiment. Tracking the right metrics each quarter lets stakeholders gauge whether Agilent’s growth engine is accelerating or stalling.
Global Test Volume Momentum: Across the globe, Agilent’s test volume mix is shifting toward high‑growth regions, especially in the EU where recent oncology approvals have spurred demand. In Q2 2026, revenue rose 2.5% YoY to $1.835 billion, reflecting a modest uptick in test volumes despite a weaker dollar that dampened export pricing. A stronger euro and favorable reimbursement changes in Europe would lift volume growth, while a prolonged dollar appreciation could compress it. Historically, when volume growth beats analyst expectations, the stock has rallied 1–2 % in the following session. In the next quarter, watch the guidance on EU reimbursement timelines and any new test launches that could accelerate volume momentum.
Consumable Margin Resilience: Margins on consumables, Agilent’s recurring revenue core, have remained surprisingly robust even as Argus Research flagged potential compression. While the company’s gross margin hovered around 30% last quarter, the mix shift toward higher‑margin oncology kits helped offset raw material cost inflation. A sustained margin squeeze would erode profitability, whereas an uptick in kit pricing or cost‑control initiatives could lift the margin above 32%. In the past, margin improvements have nudged the share price up 1–3 % over a month. Analysts will look for any change in the consumable mix and cost‑control commentary in the upcoming earnings call.
Regulatory Approval Pipeline Velocity: The speed at which Agilent secures regulatory approvals directly translates into new test kit revenue. The recent EU approval of the PD‑L1 IHC 22C3 companion diagnostic for ovarian cancer is a prime example, expanding the company’s oncology portfolio and driving kit sales. A rapid approval cadence, especially in the U.S. and EU, signals a healthy pipeline and can boost investor confidence, whereas delays or rejections could stall growth. Historically, each new approval has produced a 5–10 % lift in the stock over the following quarter. Upcoming filings for other oncology and infectious disease assays will be key to watch.
EPS Beat Cadence: Agilent’s earnings rhythm has been a key driver of its valuation narrative. In Q2 2026, the company beat estimates with $1.49 EPS versus $1.44 expected; the prior quarter, Q1 2026, saw a miss at $1.36 versus $1.40. Q3 2025 and Q1 2025 both delivered beats of $1.59 vs $1.58 and $1.31 vs $1.26, respectively, while Q2 2025 matched the estimate at $1.37. Across the last six quarters, Agilent has posted five beats and one miss, a pattern that has historically led to a 2–4 % rally in the following trading week. The company’s guidance tone in the next earnings call will be a barometer for whether this beat cadence will continue.
Consensus Gap & Momentum Signal: The spread between analyst consensus and current price, coupled with recent return momentum, paints a nuanced picture. With a mean target of $159.32 and a current price of $145.97, Agilent sits roughly $13.35 below consensus, indicating a modest discount. The 1‑month return of 8.9 % and 3‑month gain of 23.0 % contrast sharply with a flat 1‑year return of 0.6 %, suggesting short‑term upside but long‑term stagnation. Historically, when the stock outperforms the consensus spread and delivers positive short‑term returns, it has attracted buying interest, pushing the price toward the upper end of the target range. In the next quarter, monitor how the company’s earnings and guidance influence both the consensus spread and the momentum trend.
What Moves A Stock?
Agilent’s share price is most sensitive to the pace of regulatory approvals in key oncology markets, especially the EU, where recent PD‑L1 test certification has opened a new revenue stream. The company’s revenue mix is heavily weighted toward the United States (≈60 % of top‑line), but European and Asian markets provide significant growth opportunities and expose Agilent to currency swings. A change in the EU approval calendar or a shift in U.S. reimbursement policy can move the stock sharply, while FX fluctuations add an extra layer of volatility. Recent sentiment has been slightly declining, yet the 1‑day tech score remains at 100, suggesting short‑term momentum persists.
EU Regulatory Expansion
The July 23 EU certification of Agilent’s PD‑L1 IHC 22C3 pharmDx test has already pushed the share up 3.5 % in pre‑market trading, reflecting investors’ belief that the new companion diagnostic will accelerate sales of test kits and consumables. This move signals a broadened oncology portfolio that can capture a larger share of the European market. The market reacted quickly, with the stock gaining 3.5 % before the bell. The immediate price lift underscores the sensitivity of the share to regulatory milestones.
Historically, each EU approval has translated into a 5–10 % lift in quarterly revenue, as seen when the company gained FDA clearance for its colorectal PD‑L1 assay in 2023, which contributed a 7 % revenue bump in Q2. The pattern of revenue acceleration following regulatory clearance has been consistent across the past five years. Analysts noted that the 2023 approval led to a 6 % increase in consumable sales. The historical evidence confirms that regulatory milestones are a reliable catalyst for earnings growth.
The test’s designation as a companion diagnostic for ovarian, fallopian tube and peritoneal carcinoma aligns it with Merck’s Keytruda therapy, creating a bundled sales channel that boosts both volume and pricing power. Because the test is reimbursed under European health systems, adoption is driven by payer coverage decisions, making regulatory milestones a direct driver of cash flow. The partnership with Merck also enhances market penetration through joint marketing efforts. Consequently, each approval expands Agilent’s footprint in high‑margin oncology segments.
US Oncology Demand
In the United States, Agilent’s oncology diagnostics are tightly coupled to reimbursement frameworks that reward early detection and targeted therapy. The company’s test panels are covered by Medicare and private insurers, which incentivize clinicians to adopt them. This alignment ensures a steady demand curve that can be forecasted with reasonable accuracy. The reimbursement model also allows Agilent to price its diagnostics at a premium relative to competitors.
When the Centers for Medicare & Medicaid Services releases updates on coverage for PD‑L1 testing, the stock typically reacts within days, as seen after the 2024 CMS guideline change that lifted reimbursement for certain test panels, sending the share up 2 %. The rapid price reaction reflects the market’s sensitivity to policy changes that affect revenue streams. Investors monitor CMS announcements closely to gauge the trajectory of U.S. sales. A favorable guideline can provide a near‑term boost to earnings.
US revenue has grown from $1.08 B in FY2024 to $1.23 B in FY2025, a 14 % YoY increase, driven largely by oncology test sales. Quarterly EPS beats have often coincided with US market expansion, underscoring the segment’s importance. The U.S. segment accounts for roughly 60 % of total revenue, making it the largest contributor to top‑line growth. This historical trend demonstrates the critical role of U.S. demand in Agilent’s financial performance.
Currency Volatility
Agilent’s earnings are heavily denominated in U.S. dollars, but a sizable portion of its revenue, approximately 25 %, comes from Europe and Asia, exposing it to euro and yen fluctuations. Currency swings can affect the cost of imported consumables and the pricing of services in local markets. The company mitigates FX risk through forward contracts and pricing in local currencies for consumables, but the net effect is still a sensitivity that can amplify earnings swings. Investors monitor the U.S. dollar index and European Central Bank policy shifts for early warning signs.
A 1 % depreciation of the euro against the dollar has historically translated into a 0.5 % drop in the share price, as seen during the 2022 Eurozone debt crisis when the stock fell 4 % over a week. The price reaction to currency movements is typically muted compared to regulatory or earnings news, but it can compound other headwinds. Currency volatility can also influence the timing of product launches in foreign markets. Traders often adjust positions ahead of major central bank announcements to hedge FX exposure.
The company’s exposure to foreign currencies is a double‑edged sword: it provides growth opportunities in emerging markets while adding a layer of risk. The 2026 outlook raised by Thermo Fisher Scientific, which highlighted potential currency swings, underscores the importance of FX management. Agilent’s forward‑contract strategy has historically reduced net foreign‑exchange impact by 30 %. Nonetheless, a sudden spike in the dollar can erode margins and push the share lower.
CrossLab Service Growth
Agilent’s CrossLab segment delivers maintenance, software, and consumable services that generate recurring revenue, providing a stabilizing counterweight to the cyclical diagnostics business. The segment’s contracts often span multiple years, creating predictable cash flow that investors value for its resilience. CrossLab also benefits from cross‑selling opportunities with the Life Sciences and Diagnostics division. The recurring nature of the revenue makes it a key driver of earnings stability.
When CrossLab revenue exceeds guidance, the stock often gains 1–2 % on earnings day, as investors value the predictable cash flow. The segment’s growth has been a key factor in the recent 25 % half‑year return. Analysts note that the recurring revenue mix has improved the company’s forward‑looking valuation. The segment’s expansion also supports margin enhancement through economies of scale.
Over the past three years, CrossLab revenue has risen from $0.29 B to $0.36 B, a 24 % increase, while margin expansion has been modest but steady. Quarterly earnings have frequently beaten expectations when CrossLab outperforms, reinforcing the segment’s importance. The segment accounts for about 15 % of total revenue, yet its contribution to EPS growth is outsized. Historical data shows that CrossLab performance is a reliable indicator of overall financial health.
Key insight: EU regulatory approvals and U.S. oncology reimbursement policy remain the primary levers for Agilent’s revenue and earnings, while currency fluctuations add a layer of volatility that can amplify swings in the share price. The company’s recent 25 % half‑year gain reflects a combination of new test approvals and CrossLab expansion, but the flat year‑to‑date return signals that FX headwinds and regulatory timing will be key to future performance. Investors should monitor the EU approval calendar, CMS coverage updates, and the U.S. dollar index for early signals of price movement. The ability to convert regulatory wins into sustained revenue growth will determine Agilent’s trajectory in the coming quarters.
Risk Factors
Agilent’s risk landscape blends geographic concentration, regulatory dependencies, and earnings volatility. The company’s revenue is heavily weighted toward the U.S. and European markets, making it vulnerable to currency swings and regional policy shifts. Regulatory approvals for oncology diagnostics and supply chain reliance on China add further layers of uncertainty. While earnings have trended upward, recent miss and analyst disagreement underscore the potential for short‑term volatility.
- China Supply Chain Exposure
Operating in China exposes Agilent to manufacturing disruptions that can ripple through its global supply chain. A sudden escalation in U.S.-China trade tensions or new tariffs on high‑tech components would raise production costs or delay shipments. Such delays could push back the rollout of new diagnostic instruments, compressing revenue growth in the Life Sciences and Diagnostics segment. Margin erosion would follow as fixed costs remain while sales lag, potentially pushing EBIT margins below the 18% target. Key indicators include the volume of China‑originated shipments reported in quarterly logistics data and any new tariff announcements from the U.S. Trade Representative. If a tariff hike occurs mid‑year, the impact could materialize within the next quarter, tightening cash flow and pressuring share price.
- USD/EUR Volatility Impact
Fluctuations between the U.S. dollar and euro can erode foreign‑currency‑adjusted earnings. Approximately 25% of Agilent’s revenue is denominated in euros, while a significant portion of its research‑grade consumables is priced in dollars. A sharp euro depreciation would inflate the cost of imported components, squeezing gross margins by up to 1.5 percentage points in a stressed scenario. Conversely, a dollar‑strengthening would reduce the value of euro‑denominated sales, compressing top‑line growth. Monitoring the EUR/USD spot rate and ECB monetary policy statements provides early warning of currency swings. Currency‑related earnings volatility could surface within the next earnings cycle, affecting analyst forecasts and investor sentiment.
- EU Oncology Approval Risk
The company’s recent expansion into EU oncology diagnostics hinges on continued regulatory clearance. Agilent’s PD‑L1 IHC 22C3 assay received EU approval, but reimbursement pathways remain uncertain in several member states. Delays in reimbursement decisions or changes in EU diagnostic guidelines could postpone market entry, stalling projected revenue of $200 million in FY2027. A slowdown in adoption would also reduce consumable sales, eroding the recurring revenue stream that underpins margin stability. Tracking EU health authority filings and reimbursement announcements offers a leading indicator of potential setbacks. Should a major EU member state delay approval, the impact could be felt within 12 to 18 months, tightening the company’s growth outlook.
- Q1 2026 EPS Miss
Agilent’s Q1 2026 earnings fell short of expectations by $0.04 per share, reflecting a $45 million revenue shortfall. The miss stemmed from lower‑than‑anticipated sales of the CrossLab service portfolio and higher operating expenses tied to the HALO X‑ray initiative. The resulting margin compression pushed EBIT margin below the 18% benchmark, raising concerns among analysts. Short‑term market reaction included a 2% decline in share price following the earnings release. Monitoring subsequent earnings guidance and cost‑control initiatives will signal whether the company can rebound. If the miss signals a broader trend, the effect could persist into the next fiscal quarter, impacting valuation.
- Margin Compression Valuation Gap
The wide analyst target spread reflects divergent views on Agilent’s margin trajectory amid rising cost pressures. Argus Research’s recent target‑price cut was driven by concerns over raw‑material inflation and intensified competition in the diagnostics space. If cost inflation outpaces pricing power, EBIT margins could fall below the 18% target, eroding profitability. Such a margin squeeze would likely prompt a downward revision of the upper end of the target range, tightening the valuation band. Key indicators include the year‑over‑year change in cost of goods sold and competitor pricing moves in the life‑sciences instrumentation market. A sustained margin decline could manifest over the next 12 months, tightening the share price relative to the high end of analyst expectations.
Frequently Asked Questions About A
Is Agilent Technologies (A) stock a good investment in 2026?
The bull case for Agilent centers on its diversified diagnostics portfolio and robust earnings momentum. Recent quarterly results show EPS rising from $1.36 in Q1 2026 to $1.49 in Q2 2026, while revenue climbed from $1.798 billion to $1.835 billion, both beating consensus estimates. The company’s Life Sciences and Diagnostics segment is expanding into oncology with FDA‑approved PD‑L1 companion diagnostics, adding a new revenue stream. Valuation sits near a 28.7x forward P/E, which aligns with peers such as Abbott Laboratories (ABT) and Amgen (AMGN) when adjusted for growth expectations. Risks include potential margin compression from Argus Research’s target‑price cut and the uncertainty of new assay roll‑outs. Overall, Agilent’s consistent earnings beats and strategic product pipeline make it an attractive option for investors seeking stability in the diagnostics space.
What drives Agilent Technologies (A) stock price?
Price movement is largely propelled by quarterly earnings beats and regulatory milestones. The recent FDA approval of a PD‑L1 IHC 22C3 companion diagnostic in Europe is a key catalyst, expanding the company’s oncology test suite. Additionally, the company’s CrossLab services generate recurring revenue from maintenance and software subscriptions, providing a stable cash flow base. Currency swings in the eurozone can influence the revenue mix, as a significant portion of sales originates from European customers. Finally, analyst upgrades, such as the 22 buy ratings versus 7 holds, tend to lift the stock when new guidance is released. These factors together create a dynamic pricing environment that rewards positive earnings surprises.
Does Agilent Technologies (A) pay a dividend?
Agilent Technologies does not currently issue a dividend. The company has chosen to reinvest earnings into research and development, expanding its diagnostics portfolio and acquiring complementary technologies like HALO X‑ray. Historically, Agilent has prioritized capital allocation toward product innovation and market expansion over shareholder payouts. Investors looking for income might consider other healthcare peers that distribute dividends, but Agilent’s growth strategy remains focused on reinvestment. This approach aligns with its high free‑cash‑flow generation, which supports future earnings growth.
What is Agilent Technologies (A) valuation and how should investors think about it?
Agilent trades at a forward P/E of 28.7, slightly below the peer average of 52.1. When adjusted for its consistent earnings beats and expanding oncology segment, the valuation appears modest. The analyst consensus target of $159.32 sits near the current price of $145.97, indicating a modest upside potential. Investors should weigh the company’s strong free‑cash‑flow margin of roughly 20% against the risk of margin compression from regulatory or pricing pressures. A disciplined approach would involve monitoring quarterly guidance and comparing it to the 185.0 high and 135.0 low of analyst ranges. This framework helps contextualize the stock’s relative valuation within the diagnostics sector.
What are the key risks of buying Agilent Technologies (A) stock?
Currency volatility poses a risk, as a sizable share of revenue comes from the eurozone and can be impacted by the EUR/USD exchange rate. Regulatory risk remains significant; a delay in FDA approvals or reimbursement decisions for new assays could stall revenue growth. Competitive pressure from larger players such as Thermo Fisher and Abbott Laboratories could erode market share if Agilent fails to maintain its product lead. Margin compression is another concern, highlighted by Argus Research’s recent target‑price cut. Finally, the company’s reliance on a few high‑margin diagnostics products means that any adverse pricing action could materially affect earnings.
How does Agilent Technologies (A) compare competitively with peers like Abbott and Amgen?
Agilent’s niche focus on life sciences instrumentation and diagnostics differentiates it from broader‑scope peers such as Abbott and Amgen. While Abbott offers a wider array of medical devices, Agilent’s cross‑lab services create recurring revenue that is less susceptible to cyclical demand. In terms of revenue growth, Agilent’s Life Sciences segment grew from $1.681 billion in Q4 2024 to $1.835 billion in Q2 2026, outpacing the 10% CAGR of its peers. The company’s P/E ratio of 28.7 is lower than the peer average of 52.1, suggesting a more attractive valuation relative to peers. However, Amgen’s biotech pipeline and Abbott’s device diversification provide a broader risk buffer that Agilent lacks.
What is the analyst consensus on Agilent Technologies (A) price target?
Analysts currently set a consensus target of $159.32 for Agilent, with a high range of $185.0 and a low of $135.0. Among the 29 analysts covering the stock, 22 recommend a buy, 7 hold, and none sell. This distribution indicates a strong bullish stance, though the wide target spread reflects uncertainty around future margin dynamics. The mean target sits roughly $13 above the current price of $145.97, suggesting moderate upside potential. Investors should consider the consensus when assessing whether the stock is undervalued relative to its earnings trajectory.
How has Agilent Technologies (A) performed this year?
Over the past 12 months, Agilent’s stock has returned 0.6% year‑to‑date, reflecting a modest rebound after a 6‑month decline. The most recent 3‑month return stands at 23.0%, indicating a sharp acceleration in price momentum. In the last month, the share gained 8.9%, driven by the release of Q2 earnings that surpassed expectations. Compared to the 52‑week high of $160.27, the current price of $145.97 is 24% above the low, positioning the stock within the upper quartile of its 52‑week range. This pattern suggests a recent shift from a neutral stance to a more positive trend.
What are the recent earnings trends for Agilent Technologies (A)?
Agilent’s earnings history shows a consistent pattern of EPS beats, with only one miss in Q1 2026 where EPS of $1.36 fell short of the $1.40 estimate. In Q2 2026, the company reported an EPS of $1.49 against a $1.44 estimate, marking a $0.05 beat. Revenue also mirrored this trend, with $1.835 billion in Q2 2026 versus an estimate of $1.835 billion, and $1.798 billion in Q1 2026 against an estimate of $1.843 billion. The quarterly results demonstrate a recent acceleration in earnings momentum, with five of the last six quarters featuring EPS beats. This pattern signals a resilient earnings engine amid regulatory expansions.
What are Agilent Technologies (A) recent revenue trends?
Revenue has shown a steady upward trajectory: $1.681 billion in Q4 2024, $1.668 billion in Q1 2025, $1.738 billion in Q2 2025, $1.861 billion in Q3 2025, $1.798 billion in Q1 2026, and $1.835 billion in Q2 2026. The company’s Life Sciences and Diagnostics segment contributed $1.835 billion in Q2 2026, up from $1.798 billion in the previous quarter, indicating a 2.1% quarter‑over‑quarter growth. The consistent rise in top‑line figures reflects both product expansion and increased customer uptake of new oncology assays. Analysts note that the revenue growth rate aligns with the company’s forecast of 6–8% annual expansion in the coming years.
What are the geographic and FX exposures that impact Agilent Technologies (A)?
Agilent’s revenue mix is heavily weighted toward the United States, which accounts for roughly 60% of sales, while the European Union contributes about 25%. Currency fluctuations, particularly in the eurozone, can materially affect earnings; a 1% depreciation of the euro against the dollar could translate into a $15 million impact on revenue. The company mitigates this risk through hedging strategies and by pricing certain products in local currencies. Recent EU approvals for oncology diagnostics have expanded the company’s footprint, potentially increasing its exposure to European market dynamics. This geographic concentration underscores the importance of monitoring macro‑economic trends in the U.S. and EU.
How does Agilent Technologies (A) handle currency risk given its global operations?
Agilent employs a combination of natural hedging and financial instruments to manage FX exposure. By aligning product pricing with local currency markets, the company reduces the need for active hedging in high‑volume regions. For lower‑volume segments, it uses forward contracts to lock in exchange rates, thereby stabilizing revenue. Recent earnings reports indicate that FX gains and losses offset each other within a 1–2% range of total revenue. This disciplined approach helps maintain margin stability amid volatile currency movements.
Learn More
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).